REVIEW OF SAFETY AND TOLERANCE OF OMALIZUMAB
Abstract
Key words: children, bronchial asthma, monoclonal anti Ige antibodies.
About the Author
A.V. Emel'yanovRussian Federation
References
1. Djukanovich R., Wilson S.J., Kraft M. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 2004; 170 (6): 583–593.
2. Global Initiative for Аsthma. NHLB/WHO Workshop Report. 2007. 103 с.
3. Walker S., Monteil M., Phelan K. et al. Anti–IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2006; 2: CD003559.
4. Deniz Y.M., Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin. Rev. Allergy Immunol. 2005; 29 (1): 31–48.
5. Cox L., Platt-Mills T., Finegold I. et al. American Academy of Allergy Asthma Immunology/American College of Asthma, Allergy and Immunology Join Task Report on omalizumab associate anaphylaxis. J. Allergy Clin. Immunol. 2007; 120 (7): 1373–1377
6. Giavina-Banchi P., Giavina-Banchi M., Agondi R. et al. Omalizumab and Churg–Strauss syndrome. J. Allergy Clin. Immunol. 2008; 122 (1): 217.
Review
For citations:
Emel'yanov A. REVIEW OF SAFETY AND TOLERANCE OF OMALIZUMAB. Current Pediatrics. 2008;7(5):87-90.
Email this article 
